Taiho Oncology, Inc.
Amit Shah, Ph.D. has over 20 years of work experience in the pharmaceutical and research industry. Currently, they are working as the Director of Product Development at Taiho Oncology, Inc. where they started in July 2020. Prior to their current role, Amit worked as an Associate Director of Product Development at Alvogen from 2017 to 2020. From 2014 to 2017, they served as a Sr. Manager in R&D at Impax Laboratories. Before that, Amit held various positions at Frontage Laboratories, Inc. starting as a Sr. Scientist from 2005 to 2011, and later advancing to the role of Principal Scientist and Associate Director from 2011 to 2014. Amit began their career as a Research Associate at the University of Mississippi in 2000 and also worked as an intern at MD Anderson Cancer Center in 2004. Amit Shah's expertise lies in product development and research within the pharmaceutical industry.
Amit Shah, Ph.D. completed their Bachelor of Science degree in Pharmacy from MET Pharmacy from 1996 to 2000. They then pursued their Ph.D. in Pharmaceutics from the University of Mississippi, School of Pharmacy from 2000 to 2005.
This person is not in any teams
Taiho Oncology, Inc.
2 followers
The mission of Taiho Oncology, Inc. is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a world-class clinical development organization. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company’s European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com